Xeris Biopharma Holdings Inc. has outlined a strategic roadmap aimed at achieving long-term growth and value creation. The company plans to leverage its financial strength for self-funding both near- and long-term growth, driven by rapid revenue growth and disciplined capital management. A key component of this strategy is the anticipated revenue acceleration of Recorlev®, which is expected to mark a pivotal growth phase. Xeris has set a 2025 revenue target between $260 million and $275 million, with intentions to remain adjusted EBITDA positive. Looking further ahead, the company projects total revenue to reach approximately $750 million by 2030, led by Recorlev®. By 2035, Recorlev® is anticipated to achieve annual net revenue of approximately $1 billion, while XP-8121 is expected to reach peak net revenue of $1 to $3 billion. These projections are part of Xeris's commitment to delivering innovative solutions and addressing unmet medical needs.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。